Recognizing RSV: Symptoms, Diagnosis, and Treatment
The most common symptoms associated with RSV are cough (85%-95%), shortness of breath (51%-93%), wheezing (33%-90%), rhinorrhea, fever, fatigue, and anorexia.1 Symptoms can range from mild upper respiratory infection to severe pneumonia and respiratory failure, particularly in high-risk older adults. When comparing RSV with influenza, RSV has a slower onset of 4 to 7 days, vs influenza's 2 to 3 days, with peak symptoms occurring at 7 to 13 days for RSV compared with 2 to 3 days for influenza.1 High fever and severe myalgia are more common with influenza, whereas cough and wheezing are more predominant with RSV.
Because symptoms between influenza and RSV overlap significantly, laboratory testing is required for a definitive diagnosis. The gold standard for RSV diagnosis is reverse transcriptase polymerase chain reaction testing on a nasal swab; rapid antigen tests are available but are less sensitive in adults.1 Pharmacists should encourage RSV testing alongside influenza and COVID-19 testing during respiratory season, especially in high-risk older adult patients.
Currently, there is no approved antiviral for RSV in adults. Management is supportive, including fluid administration, antipyretics, and supplemental oxygen as needed.1 Ribavirin (Rebetol; Merck) is the only FDA-approved antiviral for RSV, although its indication is limited to infants; off-label use in severely immunocompromised adults exists but is based on limited evidence.1 Several antivirals are in development, but none have been approved for adult use. This treatment gap is what makes RSV fundamentally different from influenza: vaccination remains the only evidence-based intervention available for older adults, making prevention that much more important.3
Some institutions are utilizing palivizumab as a means of RSV prophylactic therapy in high-risk infants.4 It has historically been administered on a fixed schedule with no regard to specific patient factors, but implementation of pharmacist-driven flex-schedule administration has promoted better patient outcomes.4 Although this therapy is not used in older adults, it shows the impact that pharmacists make by providing expertise on patient-specific dosing and administration schedules. This same unique knowledge can be used to individualize vaccine scheduling in older adults and help distinguish when patients may be at higher risk.
Navigating the Approved RSV Vaccines
All 3 approved RSV vaccines (Arexvy from GSK, Abrysvo from Pfizer, and Mresvia from Moderna) work by targeting the prefusion F protein, the form of RSV's fusion protein that generates the strongest neutralizing antibody response. Arexvy and Abrysvo were approved by the FDA in May 2023, and mRESVIA received FDA approval in May 2024.3 Because each vaccine was evaluated using different trial designs, populations, and seasons, direct comparisons between them are not appropriate. Each of the 3 vaccines is effective, but the choice depends on individual patient factors and availability.3 Arexvy contains an adjuvant, an ingredient that helps create a stronger immune response, which is particularly relevant for the oldest or frailest patients whose immune systems may respond less robustly to vaccination alone.1 Both Arexvy and Abrysvo demonstrated efficacy through 2 RSV seasons, and data suggest that a single dose is as effective as annual revaccination.1 mRESVIA is available as a prefilled syringe, which requires less preparation time and reduces the potential for administration errors.3 Notably, Abrysvo is the only vaccine of the 3 approved for use during pregnancy at 24 to 36 weeks’ gestation, providing passive protection to newborns.3 No single vaccine is superior; the optimal choice depends on individual patient factors and availability.
The CDC's 2024 updated recommendations advise that all adults aged 75 and older receive a single dose of any approved RSV vaccine.2 For adults aged 60 to 74 years, vaccination is recommended for those with chronic conditions such as COPD, CHF, CKD, diabetes, or obesity, as well as those residing in nursing homes or long-term care facilities.2 Previously vaccinated patients should not receive another dose, as a single dose provides protection for at least 2 RSV seasons. Vaccination should ideally be administered in late summer or early fall, before the RSV season begins.2 For adults aged 60 to 74 years, the CDC employs a shared decision-making (SDM) framework, meaning vaccination is not an automatic recommendation, but rather requires an informed conversation between the patient and their provider.2
About the Authors
Amber Gilliam and Lynn Medal are PharmD candidates at the Touro University California College of Pharmacy.
Shane Desselle, RPh, PhD, is a professor of social and behavioral pharmacy at the Touro University California College of Pharmacy.
The Pharmacist’s Role in Closing the Prevention Gap
A recent study showed that 78% percent of patients receiving RSV vaccination education at a community pharmacy had not received any RSV education from their primary care provider.5 Along with lack of RSV education, patients often have hesitancy toward vaccines due to risk of adverse effects and misunderstanding of vaccine importance as prophylactic therapy.5 This is one area in which pharmacists can play an important role. An SDM discussion should cover a patient's risk factors, available vaccine options, expected benefits, potential adverse effects, and the opportunity to coadminister the RSV vaccine alongside the seasonal influenza vaccine.3 Patients in community pharmacy settings were observed to be more likely to receive an RSV vaccine after consulting with the pharmacist.4
RSV may have long been considered a pediatric disease, but with 3 vaccines now approved and pharmacists at the forefront of patient education, that narrative is finally changing. Pharmacists have significant opportunities to improve therapies for older adults affected by the condition.
REFERENCES
Alfano F, Bigoni T, Caggiano FP, Papi A. Respiratory syncytial virus infection in older adults: an update. Drugs Aging. 2024;41(6):487-505. doi:10.1007/s40266-024-01118-9
Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. Am J Transplant. 2023;23(10):1631-1640. doi:10.1016/j.ajt.2023.09.003
Andreoni M, Bonanni P, Gabutti G, Maggi S, Siliquini R, Ungar A. RSV vaccination as the optimal prevention strategy for older adults. Infez Med. 2024;32(4):478-488. doi:10.53854/liim-3204-6
Weaver KL, Bondi DS, Shah PA, Bhagat PH. Evaluation of appropriateness and cost savings of pharmacist-driven palivizumab ordering. J Pediatr Pharmacol Ther. 2020;25(7):636-641. doi:10.5863/1551-6776-25.7.636
Vascimini A, Deravi M, Perez G, et al. Respiratory syncytial virus (RSV): independent community pharmacy impact in promoting prevention through immunization. J Pharm Technol. 2025;41(1):13-17. doi:10.1177/87551225241285324